Open AccessP650: A FIRST‐IN‐HUMAN PHASE 1 TRIAL OF NX‐5948, AN ORAL BTK DEGRADER, IN PATIENTS WITH RELAPSED AND REFRACTORY B‐CELL MALIGNANCIES
Author(s) -
Linton K.,
Collins G. P.,
ElSharkawi D.,
Mous R.,
Forconi F.,
Tan M.,
Nandakumar S.,
Meredith E.,
Jameson K. L.,
Injac S. G.,
Doorduijn J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845484.57038.64
Subject(s) - ibrutinib , bruton's tyrosine kinase , chronic lymphocytic leukemia , cancer research , mantle cell lymphoma , waldenstrom macroglobulinemia , lymphoma , b cell receptor , breakpoint cluster region , medicine , b cell , immunology , tyrosine kinase , leukemia , antibody , receptor